Drug therapy of parkinsonism.
D000547:Amantadine / Q000627:therapeutic use; D000639:Amitriptyline / Q000627:therapeutic use; D000661:Amphetamine / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004336:Drug Antagonism; D004357:Drug Synergism; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008750:Methyldopa / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D010640:Phenothiazines / Q000627:therapeutic use
D000978:Antiparkinson Agents; D008996:Monoamine Oxidase Inhibitors; D010276:Parasympatholytics; D010640:Phenothiazines; D000639:Amitriptyline; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D000547:Amantadine; D000661:Amphetamine; D007099:Imipramine